Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Clinical trial NCT06573138 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06573138
Sponsor: Ruijin Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Extranodal NK-T-Cell

Start date: 2024-09-01
Primary completion: 2027-07-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.